Aptinyx tumbles after pain compound misses Phase II endpoint

Aptinyx Inc. (NASDAQ:APTX) lost $11.85 (66%) to $5.98 Wednesday after it said all three doses of NYX-2925 missed the primary endpoint in a Phase II trial to treat pain associated with diabetic peripheral neuropathy. The losses wiped out more than $395 million in market cap.

The primary endpoint measured mean change in average daily pain scores on the Numerical Rating Scale from baseline to week 4. The double-blind, U.S. trial enrolled 300 patients to receive placebo or once-daily 10, 50 or 200 mg oral NYX-2925 for four weeks...